William J. Gradishar, MD, and Rita Nanda, MD, on High-Risk Breast Cancer: Results From the I-SPY 2 Trial

Posted: Monday, June 5, 2017

William J. Gradishar, MD, of the Robert H. Lurie Comprehensive Cancer Center of Northwestern University, and Rita Nanda, MD, of the University of Chicago, discussed study findings on pembrolizumab plus standard neoadjuvant therapy for high-risk disease.